Zevra Therapeutics Newsroom

Cantor Fitzgerald Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $25

Moomoo NewsJan 8 07:34 ET · Ratings

Zevra Therapeutics (ZVRA) Receives a Buy From Cantor Fitzgerald

TipRanksJan 8 07:07 ET · Ratings

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

Yahoo FinanceDec 27, 2024 05:26 ET

Top Picks for 2025 in Healthcare, Consumer, Tech, Industrials, Energy and More

Seeking AlphaDec 17, 2024 13:46 ET

Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

GlobeNewswireDec 17, 2024 07:30 ET

Zevra Therapeutics Restructures to Focus on Rare Diseases

TipRanksDec 6, 2024 17:48 ET

Zevra Therapeutics Announces Departure of CDO Christal Mickle, CSO Sven Guenther

TipRanksDec 6, 2024 17:15 ET

Express News | Zevra Therapeutics Inc - Christal M.m. Mickle, Chief Development Officer, and Sven Guenther, Ph.d., Chief Scientific Officer, to Depart Co

ReutersDec 6, 2024 17:01 ET

Express News | Zevra Therapeutics Inc - Zevra Has Discontinued Its in-House Drug Discovery Activities

ReutersDec 6, 2024 17:01 ET

Express News | Zevra Therapeutics Inc - to Close Laboratory Facilities in Iowa and Virginia

ReutersDec 6, 2024 17:01 ET

Express News | Zevra Therapeutics Inc - Eliminates Positions in Chemistry, Manufacturing and Controls and Clinical Development

ReutersDec 6, 2024 17:00 ET

Express News | Zevra Therapeutics Inc - Consolidates Development and Scientific Functions Under Cmo Adrian Quartel

ReutersDec 6, 2024 17:00 ET

Press Release: Zevra Therapeutics Announces Organizational Changes

Dow JonesDec 6, 2024 17:00 ET

Express News | Zevra Therapeutics Announces Organizational Changes

ReutersDec 6, 2024 17:00 ET

Zevra Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswireNov 26, 2024 07:30 ET

JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17

Moomoo NewsNov 21, 2024 19:31 ET · Ratings

Zevra Therapeutics Announces Availability of MIPLYFFA, First FDA-Approved Treatment for Niemann-Pick Disease Type C, Through AmplifyAssist Patient Support Program

Quiver QuantitativeNov 21, 2024 17:02 ET

Express News | Zevra Therapeutics Announces U.S. Commercial Availability of Miplyffa™ (Arimoclomol) for Treatment of Niemann-Pick Disease Type C

ReutersNov 21, 2024 16:51 ET

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C

GlobeNewswireNov 21, 2024 16:51 ET

Zevra Therapeutics Gains Momentum With Miplyffa Approval and Market Expansion Potential in Rare Disease Treatment

TipRanksNov 21, 2024 07:16 ET